Search
Congratulations to three The Kids Research Institute Australia researchers, who have been awarded funding from the Raine Medical Research Foundation.
Earlier this week ten emerging researchers took to the stage to pitch their projects to a room full of excited and engaged philanthropists who share our vision of happy, healthy kids.
A project that will investigate the role of Australian fathers in their children’s wellbeing and another which aims to help parents grapple with the digital world and its role in teens’ mental health have received significant funding from the Australian Research Council.
The Kids Research Institute Australia has been awarded a prestigious National Health and Medical Research Council (NHMRC) tender to lead the national review of the revised Draft Statement on Consumer and Community Involvement in Health and Medical Research.
The Kids Research Institute Australia has welcomed a landmark report which reveals every dollar invested in WA’s medical research sector is more than doubled when it comes to return on investment to our economy.
The Kids Research Institute Australia and Curtin University will work together as part of a new agreement focused on enhancing children’s health and medical research in WA.
The Kids Research Institute Australia is pleased to share in $490,000 in State Government funding designed to provide vital support to WA’s innovation sector in the wake of COVID-19.
Five The Kids Research Institute Australia researchers and a popular Institute-led science festival for kids have been named as finalists in the 2024 Premier’s Science Awards.
Diarrhoea remains a leading cause of mortality among children under five years of age, with over 99 % of deaths occurring in low- and middle-income countries. Poor water quality, inadequate sanitation, poverty, undernutrition, and limited healthcare access contribute to this lingering problem, together with emerging environmental stressors driven by climate change.
Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.